In vitro susceptibility testing of amorolfine in pathogenic fungi isolated from dermatomycosis patients in China

Mycoses

Volumn 47, Issue 9-10, 2004, Pages 402-406

  Li, Ruoyo Y ^a   Wan, Z ^a   Wang, A P ^a   Shen, Y N ^b   Lu, C M ^c   Li, M ^b   Xi, L Y ^c   Liu, W D ^b   Zeng, F Q ^c  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b University of Chinese Medicine   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Amorolfine; Antifungal susceptibility; Dermatophytes; Molds; Yeasts

Indexed keywords

AMOROLFINE;

ACREMONIUM; ARTICLE; ASPERGILLUS FLAVUS; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CHINA; DERMATOMYCOSIS; DERMATOPHYTE; DRUG EFFICACY; DRUG SENSITIVITY; EPIDERMOPHYTON FLOCCOSUM; FUNGAL STRAIN; FUNGUS ISOLATION; FUSARIUM SOLANI; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ONYCHOMYCOSIS; PRIORITY JOURNAL; SCOPULARIOPSIS BREVICAULIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIFUNGAL AGENTS; CANDIDA; CHINA; DERMATOMYCOSES; DRUG EVALUATION, PRECLINICAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MORPHOLINES; TRICHOPHYTON;

ARTHRODERMA BENHAMIAE; ARTHRODERMATACEAE; ASPERGILLUS; ASPERGILLUS FLAVUS; CANDIDA; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; EPIDERMOPHYTON FLOCCOSUM; FUNGI; FUSARIUM; FUSARIUM SOLANI; SCOPULARIOPSIS; SCOPULARIOPSIS BREVICAULIS; TINEA; TRICHOPHYTON; TRICHOPHYTON RUBRUM;

EID: 7944232210     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2004.01014.x     Document Type: Article

References (10)

1. Polak AM. Preclinical data and mode of action of amorolfine. Chin Exp Dermatol 1992; 1: 8-12.
2. Jessup CJ, Warner J, Isham N, Hasan I, Ghannum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-14.
3. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard. NCCLS Document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards. 1997.
4. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility of Conidium-forming Filamentous Fungi. Proposed Standard M38-P. Wayne. PA: National Committee for Clinical Laboratory Standards, 1998.
5. Cheng S, Chong L. A prospective epidemiological study on tinea pedis and onychomycosis in Hong Kong. Chin Med J (Engl) 2002; 115: 860-5.
6. Wang AP, Li RY, Wang DL et al. Analysis of 766 isolates from onychomycosis patients. Chin J Dermatol 1995; 32: 26-8.
7. Hiratani T, Asagi Y, Matsusaka A, Uchida K, Yamaguchi H. In vitro antifungal activity of amorolfine, a new morpholine antimycotic agent. Jpn J Antibiot 1991; 44: 993-1006.
8. Uchida K, Aoki K, Yamaguchi H. In vitro antifungal activities of amorolfine against fresh isolates from patients with cutaneous mycosis. Jpn J Antibiot 1991; 44: 1007-12.
9. Evans EG. The rationale for combination therapy. Br J Dermatol 2001; 145 (Suppl. 60): 9-13.
10. Harman S, Ashbee H, Evans EG. Combination testing of antifungals against yeast and dermatophytes. J Eur Acad Dermatol Venereol 2002; 16 (Suppl. 1): S235.